Exhibit 99.1
FOR IMMEDIATE RELEASE
GLOBAL MEDICAL REIT INC. ANNOUNCES SECOND QUARTER 2017
FINANCIAL RESULTS
Reconciliations of non-GAAP financial measures for Funds from Operations, Adjusted Funds from Operations, and Normalized Adjusted Funds from Operations are included in the financial tables at the end of this announcement.
Bethesda, MD – August 10, 2017 – Global Medical REIT Inc. (NYSE: GMRE) (the “Company”), a Maryland corporation engaged primarily in the acquisition of licensed, state-of-the-art, purpose-built healthcare facilities and the leasing of these facilities to strong clinical operators with leading market share, today announces its financial results for the three-month and six-month periods ended June 30, 2017.
2017 Second Quarter Highlights (all comparisons are to the same quarter in the prior year unless otherwise noted)
| • | Total revenue increased to $7.4 million from $1.8 million. |
| • | Net loss increased to $(0.6) million from $(0.5) million. |
| • | Adjusted Funds from Operations ("AFFO") increased to $0.14 per share from $0.02 per share. |
| • | During the second quarter, the Company completed four acquisitions containing a total of 125,966 net leasable square feet for an aggregate purchase price of approximately $39.8 million. |
| • | On June 16, 2017, the Company declared a quarterly cash dividend of $0.20 per share of common stock to stockholders of record as of June 27, 2017. On an annualized basis, this amounts to a dividend of $0.80 per share. |
| • | On June 30, 2017, the Company closed on a public underwritten offering of 3.5 million shares of its common stock, resulting in net proceeds to the Company of $29.6 million. Subsequent to quarter end, the underwriters exercised in full an option to purchase an additional 525,000 shares of common stock, resulting in additional net proceeds to the Company of $4.5 million. |
David A. Young, the Company’s Chief Executive Officer, commented, “We had a successful second quarter on multiple fronts. First and foremost, we continued to add to our portfolio, adding over 125,000 net leasable square feet and ending the quarter with over one million net leasable square feet. We also completed a successful equity offering, raising net proceeds of $34.1 million, including over-allotment option proceeds received in July, which allowed us to continue building our portfolio by helping fund this quarter’s acquisitions.”
Mr. Young continued, “As noted below, we had several acquisitions close near the end of the quarter, which due to that timing, provided minimal contribution to our operating results for the quarter. As those properties earn a full quarter’s worth of rental income going forward, our operating results will benefit accordingly.”
Acquisition Activity
Completed Acquisitions During the Second Quarter Ended June 30, 2017
The Company completed four acquisitions during the second quarter of 2017, encompassing an aggregate of 125,966 net leasable square feet for a combined purchase price of approximately $39.8 million at a weighted average cap rate of approximately 8.24%. A description of the completed acquisitions is as follows:
| • | On April 21, 2017, the Company completed the acquisition of the last remaining NOMS medical property located in Sandusky, Ohio (out of a total portfolio of seven medical properties the Company previously agreed to purchase), for a purchase price of approximately $1.05 million. The Company funded this acquisition using borrowings from its revolving credit facility. The acquisitions of the other six of the seven NOMS medical properties were completed on October 7, 2016 (five properties) and March 10, 2017 (one property). |
| • | On June 27, 2017, the Company closed on the acquisition of a family medicine clinic located in Brockport, New York (the “Brockport Facility”) for a purchase price of $8.67 million. Upon the closing of this acquisition, the Company assumed the seller’s interest, as lessor, in the lease of the Brockport Facility to The Unity Hospital of Rochester. The lease has a remaining lease term of approximately 10 years. The Company funded this acquisition using borrowings from its revolving credit facility. |
| • | On June 27, 2017, the Company closed on the acquisition of a gastroenterology clinic located in Flower Mound, Texas (the “Flower Mound Facility”) for a purchase price of $4.05 million. Upon the closing of this acquisition, the Company assumed the seller’s interest, as lessor, in the lease of the Flower Mound Facility to Lone Star Endoscopy Center, LLC. The lease has a remaining lease term of approximately nine years. The Company funded this acquisition using borrowings from its revolving credit facility. |
| • | On June 30, 2017, the Company closed on the acquisition of a hospital located in Sherman, Texas for a purchase price of $26 million. Upon closing of this acquisition, the Company leased the property back to the seller, SDB Partners, by entering into a new triple-net lease with SDB Partners with an initial term of twenty years and two ten-year extension options. The Company funded this acquisition using borrowings from its revolving credit facility. |
Summary information about the completed acquisitions is presented in the table below:
| Q2 2017 Completed Acquisitions Summary Table | |||||
| Property | City | State | Purchase Price | Square Feet | Cap Rate1 |
| NOMS | Sandusky | OH | $1,049,493 | 5,055 | 7.69% |
| Carrus | Sherman | TX | $26,000,000 | 81,3522 | 8.80% |
| Lone Star | Flower Mound | TX | $4,050,000 | 10,062 | 7.00% |
| Unity | Brockport | NY | $8,670,000 | 29,497 | 7.20% |
| 1 | Cap rates are calculated based on current lease terms and do not give effect to future rent escalations. |
| 2 | Includes approximately 17,529 square feet of shell space, 5,529 square feet of which may be developed and leased in the future. |
2017 Second Quarter Financial Review
| • | For the three months ended June 30, 2017, total revenue increased to $7.4 million, compared with total revenue of $1.8 million for the second quarter in the prior year. The year-over-year increase was the result of increased rental revenue due to the Company’s larger property portfolio. |
| • | Net loss for the three months ended June 30, 2017 was $(0.6) million, or $(0.04) per share based on 17,644,137 basic and diluted weighted average shares outstanding, compared to net loss of $(0.5) million, or $(0.35) per share for the second quarter of the prior year based on 1,426,656 basic and diluted weighted average shares outstanding. The year-over-year increase was primarily due to increases in general and administrative costs, depreciation expense, and interest expense, primarily as a result of the growth in the Company’s property portfolio. |
| 2 |
| • | Quarterly funds from Operations (“FFO”) per share grew to $0.10 based on 17,644,137 basic and diluted weighted average shares outstanding, compared to $0.03 for the second quarter in the prior year based on 1,426,656 basic and diluted weighted average shares outstanding. |
| • | Quarterly AFFO per share grew to $0.14 based on 17,644,137 basic and diluted weighted average shares outstanding, compared to $0.02 for the second quarter in the prior year based on 1,426,656 basic and diluted weighted average shares outstanding. |
| • | Quarterly Normalized Adjusted Funds from Operations (“Normalized AFFO”) per share grew to $0.16 based on 17,644,137 basic and diluted weighted average shares outstanding, compared to $0.02 for the second quarter in the prior year based on 1,426,656 basic and diluted weighted average shares outstanding. |
2017 Year-to-Date Financial Review
| • | For the six months ended June 30, 2017, total revenue increased to $12.1 million, compared with total revenue of $3.1 million for the comparable prior year period. |
| • | Net loss for the six months ended June 30, 2017 was $(1.9) million, or $(0.11) per share based on 17,624,906 basic and diluted weighted average shares outstanding, compared to net loss of $(2.4) million, or $(2.38) per share based on 1,025,821 basic and diluted weighted average shares outstanding for the comparable prior year period. The decrease in the net loss for the six months ended June 30, 2017, compared to the prior year period, was primarily due to increased rental revenue driven by the growth in the Company’s property portfolio. |
| • | FFO per share grew to $0.12 based on 17,624,906 basic and diluted weighted average shares outstanding, compared to $(1.46) for the comparable prior year period based on 1,025,821 basic and diluted weighted average shares outstanding. |
| • | AFFO per share grew to $0.23 based on 17,624,906 basic and diluted weighted average shares outstanding, compared to $(0.70) for the comparable prior year period based on 1,025,821 basic and diluted weighted average shares outstanding. |
| • | Normalized AFFO per share grew to $0.24 based on 17,624,906 basic and diluted weighted average shares outstanding compared to $(0.70) for the comparable prior year period based on 1,025,821 basic and diluted weighted average shares outstanding. |
Leasing Review
| • | At June 30, 2017, the Company’s total portfolio included 46 buildings leased to 35 tenants. |
| • | The Company’s portfolio contained 1,060,144 net leasable square feet as of June 30, 2017 with an overall leased occupancy rate of 100%. |
| • | The average lease term remaining for the entire portfolio was 9.4 years at June 30, 2017 with an average annual base rent of $25.37 per square foot. |
Balance Sheet Summary
| • | The Company’s cash and cash equivalents balance was $12.0 million as of June 30, 2017 compared to $19.7 million as of December 31, 2016. |
| • | The Company’s gross investment in real estate as of June 30, 2017 was $355.1 million compared to $206.6 million as of December 31, 2016. The gross investment balance includes approximately $17 million and $7 million, respectively, of intangible assets acquired net of intangible liabilities acquired. |
| 3 |
| • | The Company’s total debt, which includes outstanding borrowings on the revolving credit facility, third party debt (net of unamortized deferred financing costs), and related party debt, was $183.0 million as of June 30, 2017, compared to $66.5 million as of December 31, 2016. The Company’s weighted-average interest rate and term of its debt was 4.5% and 3.85 years, respectively, as of June 30, 2017, compared to 4.29% and 6.04 years, respectively, as of December 31, 2016. |
Earnings Call
The Company will hold its second quarter 2017 conference call on August 10, 2017, at 11:00 a.m. Eastern Time. Shareholders and other interested parties may listen to a simultaneous webcast of the conference call on the Internet via the “Investor Relations” section of the Company’s website at www.globalmedicalreit.com or by clicking on the conference call link http://globalmedicalreit.equisolvewebcast.com/q2-2017, or they may participate in the conference call by dialing 1-877-407-3948 and referencing Global Medical REIT. An audio replay of the conference call will be posted on the Company’s website.
About Global Medical REIT Inc.
Global Medical REIT Inc. is a Maryland corporation engaged primarily in the acquisition of licensed, state-of-the-art, purpose-built healthcare facilities and the leasing of these facilities to strong clinical operators with leading market share. The Company’s strategy is to produce increasing, reliable rental revenue by expanding its portfolio, and leasing its healthcare facilities to market-leading operators under long-term triple-net leases. The Company’s management team has significant healthcare, real estate and public real estate investment trust, or REIT, experience and has long-established relationships with a wide range of healthcare providers. The Company intends to elect to be taxed as a REIT for U.S. federal income tax purposes commencing with its taxable year ending December 31, 2016.
| 4 |
Forward-Looking Statements
Certain statements contained herein may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and it is the Company’s intent that any such statements be protected by the safe harbor created thereby. These forward-looking statements are identified by their use of terms and phrases such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "plan," "predict," "project," "will," "continue" and other similar terms and phrases, including references to assumption and forecasts of future results. Except for historical information, the statements set forth herein including, but not limited to, any statements regarding expected financial performance or other financial items and statements regarding future dividend payments; any statements concerning our plans, strategies, objectives and expectations for future operations and our pipeline of acquisition opportunities and expected acquisition activity, including the timing and/or successful completion of any acquisitions; any statements regarding the expected size and growth of the healthcare real estate market, and any statements regarding future economic conditions or performance are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to certain risks and uncertainties. Although the Company believes that the expectations, estimates and assumptions reflected in its forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of the Company’s forward-looking statements. Important factors that could cause the Company’s actual results to differ materially from estimates, stated expectations or projections contained in the Company’s forward-looking statements are set forth in the “Risk Factors” section of our Annual Report on Form 10-K, as amended by Amendment No. 1 and Amendment No. 2 thereto, for the year ended December 31, 2016, which were filed with the United States Securities and Exchange Commission (“SEC”) on March 27, 2017, May 5, 2017, and May 9, 2017, respectively, and elsewhere in the reports the Company has filed with the SEC, including that unfavorable global and domestic economic conditions may adversely impact the Company’s business, the Company may not be successful in completing acquisitions in its investment pipeline or that it identifies and pursues in the future, and the Company’s expenses may be higher than anticipated. You are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and undertakes no obligation, to update any forward-looking statement.
| COMPANY CONTACT: | INVESTOR RELATIONS: | |
| -OR- | ||
| Global Medical REIT Inc. | The Equity Group Inc. | |
| Danica Holley | Jeremy Hellman | |
| Chief Operating Officer | Senior Associate | |
| (202) 524-6854 / danicah@globalmedicalreit.com | (212) 836-9626 / jhellman@equityny.com | |
| Adam Prior | ||
| Senior Vice-President | ||
| (212) 836-9606 / aprior@equityny.com |
| 5 |
Global Medical REIT Inc.
Consolidated Statements of Operations
(unaudited)
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenue | ||||||||||||||||
| Rental revenue | $ | 6,666,538 | $ | 1,762,769 | $ | 11,295,797 | $ | 3,061,747 | ||||||||
| Expense recoveries | 697,639 | - | 697,639 | - | ||||||||||||
| Other income | 58,769 | 7,890 | 88,368 | 22,971 | ||||||||||||
| Total revenue | 7,422,946 | 1,770,659 | 12,081,804 | 3,084,718 | ||||||||||||
| Expenses | ||||||||||||||||
| Acquisition fees | 536,069 | - | 1,478,542 | - | ||||||||||||
| Acquisition fees – related party | - | - | - | 754,000 | ||||||||||||
| General and administrative | 2,580,874 | 368,210 | 4,198,322 | 1,256,739 | ||||||||||||
| Management fees – related party | 628,374 | 90,000 | 1,255,521 | 180,000 | ||||||||||||
| Depreciation expense | 1,850,587 | 544,002 | 3,196,640 | 942,832 | ||||||||||||
| Amortization expense | 459,308 | - | 802,908 | - | ||||||||||||
| Interest expense | 1,990,499 | 1,262,646 | 3,090,579 | 2,391,909 | ||||||||||||
| Total expenses | 8,045,711 | 2,264,858 | 14,022,512 | 5,525,480 | ||||||||||||
| Net loss | $ | (622,765 | ) | $ | (494,199 | ) | $ | (1,940,708 | ) | $ | (2,440,762 | ) | ||||
| Net loss per share – Basic and Diluted | $ | (0.04 | ) | $ | (0.35 | ) | $ | (0.11 | ) | $ | (2.38 | ) | ||||
| Weighted average shares outstanding – Basic and Diluted | 17,644,137 | 1,426,656 | 17,624,906 | 1,025,821 | ||||||||||||
| 6 |
Global Medical REIT Inc.
Consolidated Balance Sheets
| As of | ||||||||
June 30, 2017 | December 31, 2016 | |||||||
| Assets | (unaudited) | |||||||
| Investment in real estate: | ||||||||
| Land | $ | 25,822,453 | $ | 17,785,001 | ||||
| Building | 306,198,609 | 179,253,398 | ||||||
| Site improvements | 3,115,289 | 1,465,273 | ||||||
| Tenant improvements | 2,996,662 | 1,186,014 | ||||||
| 338,133,013 | 199,689,686 | |||||||
| Less: accumulated depreciation | (6,520,555 | ) | (3,323,915 | ) | ||||
| Investment in real estate, net | 331,612,458 | 196,365,771 | ||||||
| Cash | 12,033,797 | 19,671,131 | ||||||
| Restricted cash | 2,291,080 | 941,344 | ||||||
| Tenant receivables | 534,484 | 212,435 | ||||||
| Escrow deposits | 979,709 | 1,212,177 | ||||||
| Acquired lease intangible assets, net | 17,218,214 | 7,144,276 | ||||||
| Deferred assets | 1,867,010 | 704,537 | ||||||
| Deferred financing costs, net | 2,770,144 | 927,085 | ||||||
| Other assets | 88,695 | 140,374 | ||||||
| Total assets | $ | 369,395,591 | $ | 227,319,130 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 2,216,953 | $ | 573,997 | ||||
| Dividends payable | 3,700,936 | 3,604,037 | ||||||
| Security deposits and other | 2,444,842 | 719,592 | ||||||
| Due to related parties, net | 638,790 | 580,911 | ||||||
| Acquired lease intangible liability, net | 1,112,566 | 277,917 | ||||||
| Notes payable to related parties | - | 421,000 | ||||||
| Notes payable, net of unamortized discount of $995,990 and $1,061,602 at June 30, 2017 and December 31, 2016, respectively | 38,478,910 | 38,413,298 | ||||||
| Revolving credit facility | 144,500,000 | 27,700,000 | ||||||
| Total liabilities | 193,092,997 | 72,290,752 | ||||||
| Stockholders' equity: | ||||||||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding | - | - | ||||||
| Common stock $0.001 par value, 500,000,000 shares authorized at June 30, 2017 and December 31, 2016, respectively; 21,105,675 and 17,605,675 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively | 21,106 | 17,606 | ||||||
| Additional paid-in capital | 202,513,240 | 171,997,396 | ||||||
| Accumulated deficit | (26,231,752 | ) | (16,986,624 | ) | ||||
| Total stockholders' equity | 176,302,594 | 155,028,378 | ||||||
| Total liabilities and stockholders' equity | $ | 369,395,591 | $ | 227,319,130 | ||||
| 7 |
Global Medical REIT Inc.
Consolidated Statements of Cash Flows
| Six Months Ended June 30, | ||||||||
| 2017 | 2016 | |||||||
| Operating activities | ||||||||
| Net loss | $ | (1,940,708 | ) | $ | (2,440,762 | ) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||||||||
| Depreciation expense | 3,196,640 | 942,832 | ||||||
| Amortization of deferred financing costs | 499,577 | 152,845 | ||||||
| Amortization of acquired lease intangible assets | 802,908 | - | ||||||
| Amortization of above (below) market leases | (11,046 | ) | - | |||||
| Stock-based compensation expense | 1,140,437 | - | ||||||
| Capitalized deal costs charged to expense | 5,450 | - | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Restricted cash | (1,521,537 | ) | (319,499 | ) | ||||
| Tenant receivables | (322,049 | ) | - | |||||
| Deferred assets | (1,162,473 | ) | (131,419 | ) | ||||
| Accounts payable and accrued expenses | 1,394,169 | 1,241,678 | ||||||
| Security deposits and other | 1,725,250 | 319,499 | ||||||
| Accrued management fees due to related party | 7,665 | 30,000 | ||||||
| Net cash provided by (used in) operating activities | 3,814,283 | (204,826 | ) | |||||
| Investing activities | ||||||||
| Escrow deposits for purchase of properties | 249,448 | 344,310 | ||||||
| Loans repayments from (made to) related party | 40,384 | (39,040 | ) | |||||
| Pre-acquisition costs for purchase of properties | 120,691 | - | ||||||
| Purchase of land, buildings, and other tangible and intangible assets and liabilities | (148,474,478 | ) | (37,946,139 | ) | ||||
| Net cash used in investing activities | (148,063,955 | ) | (37,640,869 | ) | ||||
| Financing activities | ||||||||
| Net proceeds received from follow-on offering | 29,553,232 | - | ||||||
| Change in restricted cash | 171,801 | (210,452 | ) | |||||
| Escrow deposits required by third party lenders | (16,980 | ) | (835,162 | ) | ||||
| Loans from related party | 9,830 | 1,655,272 | ||||||
| Proceeds from notes payable from acquisitions | - | 41,320,900 | ||||||
| Payments on notes payable from acquisitions | - | (9,410,182 | ) | |||||
| Proceeds from note payable from related party | - | 450,000 | ||||||
| Repayment of note payable from related party | (421,000 | ) | - | |||||
| Proceeds from revolving credit facility, net | 116,800,000 | - | ||||||
| Payments of deferred initial public offering costs | - | (358,365 | ) | |||||
| Payments of deferred financing costs | (2,277,024 | ) | (1,090,079 | ) | ||||
| Dividends paid to stockholders | (7,207,521 | ) | (285,703 | ) | ||||
| Net cash provided by financing activities | 136,612,338 | 31,236,229 | ||||||
| Net decrease in cash and cash equivalents | (7,637,334 | ) | (6,609,466 | ) | ||||
| Cash and cash equivalents—beginning of period | 19,671,131 | 9,184,270 | ||||||
| Cash and cash equivalents—end of period | $ | 12,033,797 | $ | 2,574,804 | ||||
| Supplemental cash flow information: | ||||||||
| Cash payments for interest | $ | 2,479,834 | $ | 1,034,945 | ||||
| Noncash financing and investing activities: | ||||||||
| Accrued dividends payable | $ | 3,700,936 | $ | - | ||||
| Conversion of convertible debenture due to majority stockholder to common stock | $ | - | $ | 15,000,000 | ||||
| Accrued deferred initial public offering costs | $ | 174,325 | $ | 1,152,543 | ||||
| Reclassification of deferred follow-on offering costs to additional paid-in capital | $ | 394,092 | $ | - | ||||
| Accrued capitalized deal costs | $ | 74,462 | $ | - | ||||
| 8 |
Non-GAAP Financial Measures
FFO, AFFO, and Normalized AFFO are non-GAAP financial measures within the meaning of the rules of the SEC. The Company considers FFO, AFFO, and Normalized AFFO to be important supplemental measures of its operating performance and believes FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. In accordance with the National Association of Real Estate Investment Trusts’ (“NAREIT”) definition, FFO means net income or loss computed in accordance with generally accepted accounting principles (“GAAP”) before non-controlling interests of holders of operating partnership units, excluding gains (or losses) from sales of property and extraordinary items, plus real estate related depreciation and amortization (excluding amortization of deferred financing costs), and after adjustments for unconsolidated partnerships and joint ventures. The Company did not incur any gains or losses from the sales of property or record any adjustments for unconsolidated partnerships and joint ventures during the quarters ended June 30, 2017 and June 30, 2016. Because FFO excludes real estate related depreciation and amortization (other than amortization of deferred financing costs), the Company believes that FFO provides a performance measure that, when compared period-over-period, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from the closest GAAP measurement, net income or loss.
AFFO is a non-GAAP measure used by many investors and analysts to measure a real estate company’s operating performance by removing the effect of items that do not reflect ongoing property operations. Management calculates AFFO by modifying the NAREIT computation of FFO by adjusting it for certain cash and non-cash items and certain recurring and non-recurring items. For the Company, these items include recurring acquisition and disposition costs, loss on the extinguishment of debt, recurring straight line deferred rental revenue, recurring stock-based compensation expense, recurring amortization of deferred financing costs, recurring capital expenditures, recurring lease commissions, recurring tenant improvements and other items.
Management calculates Normalized AFFO, which is also a non-GAAP financial measure, by modifying AFFO by adjusting for non-recurring income and expenses. For the Company, these items include the costs of establishing a system of Sarbanes-Oxley-compliant internal controls and procedures and the portion of our General Counsel and Secretary’s salary for 2017 that is reimbursable by the Company to the Company’s external advisor, Inter-American Management, LLC (such reimbursement obligation expires on May 8, 2018).
Management believes that reporting AFFO in addition to FFO is a useful supplemental measure for the investment community to use when evaluating the operating performance of the Company on a comparative basis. Management also considers Normalized AFFO to be a useful measure to evaluate the Company’s operating results excluding non-recurring income and expenses. Normalized AFFO can help investors compare the operating performance of the Company between periods or as compared to other companies. The Company’s FFO, AFFO, and Normalized AFFO computations may not be comparable to FFO, AFFO, and Normalized AFFO reported by other REITs that do not compute FFO in accordance with the NAREIT definition, that interpret the NAREIT definition differently than the Company does or that compute FFO, AFFO, and Normalized AFFO in a different manner.
| 9 |
Global Medical REIT Inc.
Reconciliation of Funds from Operations (FFO)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| Net loss | $ | (622,765 | ) | $ | (494,199 | ) | $ | (1,940,708 | ) | $ | (2,440,762 | ) | ||||
| Depreciation and amortization expense | 2,309,895 | 544,002 | 3,999,548 | 942,832 | ||||||||||||
| Amortization of above (below) market leases | (2,846 | ) | - | (11,046 | ) | - | ||||||||||
| FFO | $ | 1,684,284 | $ | 49,803 | $ | 2,047,794 | $ | (1,497,930 | ) | |||||||
| FFO per Share | $ | 0.10 | $ | 0.03 | $ | 0.12 | $ | (1.46 | ) | |||||||
| Weighted Average Shares Outstanding | 17,644,137 | 1,426,656 | 17,624,906 | 1,025,821 | ||||||||||||
Global Medical REIT Inc.
Reconciliation of Adjusted Funds from Operations (AFFO)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| FFO | $ | 1,684,284 | $ | 49,803 | $ | 2,047,794 | $ | (1,497,930 | ) | |||||||
| Acquisition costs | 536,069 | - | 1,478,542 | 754,000 | ||||||||||||
| Straight line deferred rental revenue | (746,710 | ) | (81,646 | ) | (1,129,321 | ) | (131,419 | ) | ||||||||
| Stock-based compensation expense | 720,827 | - | 1,140,437 | - | ||||||||||||
| Amortization of deferred financing costs | 340,905 | 62,604 | 499,577 | 152,845 | ||||||||||||
| AFFO | $ | 2,535,375 | $ | 30,761 | $ | 4,037,029 | $ | (722,504 | ) | |||||||
| AFFO per Share | $ | 0.14 | $ | 0.02 | $ | 0.23 | $ | (0.70 | ) | |||||||
| Weighted Average Shares Outstanding | 17,644,137 | 1,426,656 | 17,624,906 | 1,025,821 | ||||||||||||
| 10 |
Global Medical REIT Inc.
Reconciliation of Normalized Adjusted Funds from Operations (Normalized AFFO)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| AFFO | $ | 2,535,375 | $ | 30,761 | $ | 4,037,029 | $ | (722,504 | ) | |||||||
| Professional fees and services related to Sarbanes-Oxley implementation | 206,122 | - | 241,338 | - | ||||||||||||
| Compensation expense reimbursement | 18,145 | - | 18,145 | - | ||||||||||||
| Normalized AFFO | $ | 2,759,642 | $ | 30,761 | $ | 4,296,512 | $ | (722,504 | ) | |||||||
| Normalized AFFO per Share | $ | 0.16 | $ | 0.02 | $ | 0.24 | $ | (0.70 | ) | |||||||
| Weighted Average Shares Outstanding | 17,644,137 | 1,426,656 | 17,624,906 | 1,025,821 | ||||||||||||
| 11 |
